HORMONE-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER: DECISION MAKING IN REAL CLINICAL PRACTICE
https://doi.org/10.37748/2687-0533-2020-1-2-6
Abstract
About the Authors
L. Yu. VladimirovaRussian Federation
Dr. Sci. (Med.), Professor, head of the tumor drug treatment department, head of the antitumor drug therapy department No. 1
SPIN: 4857–6202, AuthorID: 289090, ResearcherID: U-8132–2019, Scopus Author ID: 7004401163
63 14 line str., Rostov-on-Don 344037, Russian Federation
A. E. Storozhakova
Russian Federation
Cand. Sci. (Med.), head of the antitumor drug therapy department No. 2
SPIN: 2804–7474, AuthorID: 734057, ResearcherID: U-6202–2019, Scopus Author ID: 57045921800
63 14 line str., Rostov-on-Don 344037, Russian Federation
T. A. Snezhko
Russian Federation
Cand. Sci. (Med.), doctor of the antitumor drug therapy department No. 2
SPIN: 4479–1414, AuthorID: 706064, Scopus Author ID: 57189055248
63 14 line str., Rostov-on-Don 344037, Russian Federation
L. K. Strakhova
Russian Federation
junior researcher of the tumor drug treatment department
SPIN: 2688–1073, AuthorID: 1055704
63 14 line str., Rostov-on-Don 344037, Russian Federation
N. A. Abramova
Russian Federation
Cand. Sci. (Med.), oncologist of the antitumor drug therapy department No. 1, senior researcher of the tumor drug treatment
department
SPIN: 1784–8819, AuthorID: 734048, ResearcherID: U-6181–2019, Scopus Author ID: 56737398800
63 14 line str., Rostov-on-Don 344037, Russian Federation
S. N. Kabanov
Russian Federation
Cand. Sci. (Med.), doctor of the antitumor drug therapy department № 2
SPIN: 6369–0824, AuthorID: 794858, ResearcherID: V-3023–2019, Scopus Author ID: 57045732600
63 14 line str., Rostov-on-Don 344037, Russian Federation
E. A. Kalabanova
Russian Federation
Cand. Sci. (Med.), Senior researcher of the tumor drug treatment department
SPIN: 9090–3007, AuthorID: 734992, ResearcherID: V-2943–2019, Scopus Author ID: 57046062200
63 14 line str., Rostov-on-Don 344037, Russian Federation
N. Yu. Samaneva
Russian Federation
doctor of the antitumor drug therapy department No. 2
SPIN: 1181–0659, AuthorID: 734488, ResearcherID: AAH-7905–2019, Scopus Author ID: 57192874030
63 14 line str., Rostov-on-Don 344037, Russian Federation
Ya. V. Svetitskaya
Russian Federation
Cand. Sci. (Med.), scientific researcher of the tumor drug treatment department
SPIN: 6821–0327, AuthorID: 571593, ResearcherID: AAH-7906–2019
63 14 line str., Rostov-on-Don 344037, Russian Federation
A. V. Tishina
Russian Federation
doctor of the antitumor drug therapy department № 2
SPIN: 7686–3707, ResearcherID: H-2460–2018
63 14 line str., Rostov-on-Don 344037, Russian Federation
References
1. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002 Nov; 76(1): 27–36. https://doi.org/10.1023/a:1020299707510
2. Beaver JA, Amiri‑Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, et al. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor‑Positive, HER2‑Negative Metastatic Breast Cancer. Clin Cancer Res. 2015 Nov 1; 21(21): 4760–4766. https://doi.org/10.1158/1078–0432.CCR‑15–1185
3. Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor‑positive advanced breast cancer (FALCON): an international, randomised, double‑blind, phase 3 trial. Lancet. 2016 Dec 17; 388(10063): 2997–3005. https://doi.org/10.1016/S0140–6736(16)32389–3
4. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, et al. ESO‑ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014 Oct; 25(10): 1871–1888. https://doi.org/10.1093/annonc/mdu385
5. Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Med Chem. 2015 Aug; 7(12): 1511–1519. https://doi.org/10.4155/fmc.15.93
6. Boye E, Grallert B. The 2001 Nobel Prize in Physiology or Medicine. Tidsskr Nor Laegeforen. 2001 Dec 10; 121(30): 3500.
7. Rugo HS, Finn RS, Dieras V, Ettl J, Lipatov O, Joy A, et al. Abstract P5–21–03: Palbociclib (PAL) + letrozole (LET) as first‑line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Efficacy and safety updates with longer follow‑up across patient subgroups. Cancer Res. 2018 Feb 15; 78(4 Supplement): P5‑P5–21–03. https://doi.org/10.1158/1538–7445.SABCS17‑P5–21–03
8. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch‑Shimon S, et al. Updated results from MONALEESA‑2, a phase III trial of first‑line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor‑positive, HER2‑negative advanced breast cancer. Ann Oncol. 2018 Jul 1; 29(7): 1541–1547. https://doi.org/10.1093/annonc/mdy155
9. Goetz MP, Toi M, Campone M, Sohn J, Paluch‑Shimon S, Huober J, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017 Nov 10; 35(32): 3638–3646. https://doi.org/10.1200/JCO.2017.75.6155
10. Artamonova EV. Practical aspects of administering cyclin‑dependent kinases inhibitors: efficacy and tolerability. Journal of Tumors of the Female Reproductive System 2018; 14(1): 52–60. (In Russian).
Review
For citations:
Vladimirova L.Yu., Storozhakova A.E., Snezhko T.A., Strakhova L.K., Abramova N.A., Kabanov S.N., Kalabanova E.A., Samaneva N.Yu., Svetitskaya Ya.V., Tishina A.V. HORMONE-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER: DECISION MAKING IN REAL CLINICAL PRACTICE. South Russian Journal of Cancer. 2020;1(2):46-51. https://doi.org/10.37748/2687-0533-2020-1-2-6